Compare WBX & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WBX | ENGN |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | Spain | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.2M | 117.2M |
| IPO Year | 2021 | 2023 |
| Metric | WBX | ENGN |
|---|---|---|
| Price | $2.94 | $2.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $4.75 | ★ $21.08 |
| AVG Volume (30 Days) | 11.0K | ★ 654.6K |
| Earning Date | 05-06-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 56.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.10 | N/A |
| Revenue Next Year | $94.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.30 | $1.40 |
| 52 Week High | $7.83 | $12.25 |
| Indicator | WBX | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 62.65 |
| Support Level | $3.00 | $1.67 |
| Resistance Level | $3.19 | $7.92 |
| Average True Range (ATR) | 0.19 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 16.11 | 94.23 |
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments: Europe, the Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.